Meta-analysis reveals psychiatric risks of stimulant treatment for ADHD, suggesting non-negligible rates of psychosis in treated individuals.
A new meta‐analysis is raising fresh concerns about the psychiatric risks associated with stimulant treatment for attention‐deficit/hyperactivity disorder (ADHD). Drawing on data from nearly 400,000 individuals across 16 studies, researchers found that the occurrence of psychosis and bipolar disorder (BD) in stimulant‐treated patients was “nonnegligible.”
No takes yet. Share an insight, caveat, or question.
Valerie A. Canady (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: